SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HuMAB companies

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who wrote (187)6/21/2001 7:34:26 AM
From: nigel bates   of 1022
 
MARTINSRIED and MUNICH, Germany, June 21 /PRNewswire/ -- The Munich-based biotechnology company MorphoSys AG (Neuer Markt: MOR) confirmed that Cambridge Antibody Technology Ltd. (CAT), together with The Medical Research Council and The Scripps Research Institute, initiated a lawsuit at the United States District Court for the Southern District of California in San Diego alleging infringement of their ``Winter II'' US patent. The Winter II patent covers certain antibody expression libraries and methods of generating such libraries and was granted in the USA on June 19, 2001 (U.S. Patent No. 6,248,516).
In Europe, a related Winter II patent was granted in 1994 and MorphoSys successfully opposed it at the European Patent Office (EPO) in October 1999. In its decision in 1999, the EPO requested substantial changes in the language of the key claim in the patent, thereby significantly narrowing the scope of protection.
This new lawsuit is based on a different patent than is involved in the pending suit in the United States District Court in Washington D.C., which is based on CAT's U.S. Patent No. 5,885,793 (``Griffiths'' patent). In that case, CAT failed to obtain an infringement verdict from the jury. There are several post-trial motions pending...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext